CSPC Pharmaceutical Group Limited (CVG.F)
| Previous Close | 0.7246 |
| Open | 0.7624 |
| Bid | 0.7514 x 1500000 |
| Ask | 0.7860 x 1500000 |
| Day's Range | 0.7514 - 0.7720 |
| 52 Week Range | 0.6226 - 0.9082 |
| Volume | |
| Avg. Volume | 2,611 |
| Market Cap | 9.153B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 12.53 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.03 (4.54%) |
| Ex-Dividend Date | May 31, 2024 |
| 1y Target Est | N/A |
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
- Reuters
UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment
Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.
